Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach
about
Poor ovarian reserveThe sub-optimal response to controlled ovarian stimulation: manageable or inevitable?Maximizing the clinical utility of antimüllerian hormone testing in women's healthIndividualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practiceThe Bologna criteria for poor ovarian response: a contemporary critical appraisalThe meaning of anti-Müllerian hormone levels in patients at a high risk of poor ovarian responseAnti-Müllerian hormone: ovarian reserve testing and its potential clinical implicationsLuteal phase dynamics of follicle-stimulating and luteinizing hormones in obese and normal weight womenLive birth and perinatal outcomes following stimulated and unstimulated IVF: analysis of over two decades of a nationwide data.Is AMH Level, Independent of Age, a Predictor of Live Birth in IVF?Follicle-stimulating hormone receptor (FSHR) alternative skipping of exon 2 or 3 affects ovarian response to FSHPreserving fertility in patients undergoing treatment for breast cancer: current perspectives.Cost-effectiveness analysis comparing continuation of assisted reproductive technology with conversion to intrauterine insemination in patients with low follicle numbers.LH pretreatment as a novel strategy for poor responders.The physiology and clinical utility of anti-Mullerian hormone in women.The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature.Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy.The use of ovarian reserve markers in IVF clinical practice: a national consensus.Challenges and considerations in optimizing ovarian stimulation protocols in oncofertility patients.Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis.Cut-Off Levels of Anti-Mullerian Hormone for The Prediction of Ovarian Response, In Vitro Fertilization Outcome and Ovarian Hyperstimulation Syndrome.Anti-Mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunityHigher clinical pregnancy rates from frozen-thawed blastocyst transfers compared to fresh blastocyst transfers: a retrospective matched-cohort study.A global perspective on assisted reproductive technology fertility treatment: an 8-country fertility specialist surveyEstimating the chance of success in IVF treatment using a ranking algorithm.Antral follicle count determines poor ovarian response better than anti-Müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles.Nomogram to predict the number of oocytes retrieved in controlled ovarian stimulation.How Much Does AMH Really Vary in Normal Women?There is a Positive Correlation Between Socioeconomic Status and Ovarian Reserve in Women of Reproductive Age.Accuracy and safety verification of ovarian reserve assessment technique for ovarian tissue transplantation using optical coherence tomography in mice ovary.Evidence-based reproductive medicine: a critical appraisal.Ovarian response prediction in controlled ovarian stimulation for IVF using anti-Müllerian hormone in Chinese women: A retrospective cohort study.Anti-Müllerian hormone does not predict time to pregnancy: results of a prospective cohort study.Biomarkers of ovarian reserve.Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response.Is assessment of anti-Müllerian hormone and/or antral follicle count useful in the prediction of ovarian response in expected normal responders treated with a fixed dose of recombinant FSH and GnRH antagonists? A prospective observational study.Follicular sensitivity index (FSI): a novel tool to predict clinical pregnancy rate in IVF/ICSI cycles.Association of blood groups with ovarian reserve and outcome of in vitro fertilization treatment.Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review.A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial.
P2860
Q26744379-B4D7AB71-6335-4F97-A883-364979693B18Q26800627-DCFDFBBC-E473-4F82-9BC5-E62868130AA9Q26822937-91D70FF1-5B42-4B99-BF3B-1790DE93306BQ26829747-9D03DD4D-2291-4DB9-974D-77E174C4C88DQ27021821-18283F72-5F5C-453B-BDC5-D6CB63492B3CQ28067035-6A9487FD-B4EB-42F4-86AA-8EB7D63B4600Q28239980-F0DEBFFB-7356-4334-882D-F5032DBE9E98Q28391267-BCFE4007-D45B-409D-A07E-EE34E346BCA7Q31126515-FE8656DE-F21A-4B51-8B49-B15A0065818FQ33604947-5C6705CC-BD2E-431F-A7DF-3E0B67218349Q33810850-7F6431E9-DE63-40D7-B4CE-AA831976D007Q33939688-E95DD156-81E0-45A6-9E6D-96F0AD13CE15Q33992236-36F06DD1-4C54-4D02-82C3-5CEF0C761FF3Q34092900-55CC2325-4681-4885-82F3-21037AC4502AQ34398233-7042BCC4-3A45-4E23-AFA3-A1315FF44210Q34404612-39B23D32-3880-4F79-AB21-C3CD13005806Q34426839-A7DCBDB0-5CFE-4860-B482-DDBD721E89CAQ34500365-8C8B9FE5-2DB3-48D8-BE01-FFEC589D2ABCQ34637134-E9F5443D-9636-42F8-A8AC-15D91BC22CAEQ35856600-68277A74-A2B4-43E2-B088-567185C5D236Q35898934-45E6E465-6327-4A79-9C74-CA9837A95E0FQ36082015-154C5334-B28B-4F31-8E54-A0496773CC8DQ36192122-3FB247D4-2AE3-444A-8BFC-C5F7A393A17FQ36358138-A5825822-7914-4391-BAC4-98B2BA7469BDQ36621648-384BDB16-A259-4FEA-9F9A-FCB83B5A0EF4Q36875001-079A8C8D-8A36-44D9-94C8-42F2C184D831Q37049153-2FFDB758-53EB-432F-8443-D47AFA7DF591Q37367598-EE9B1AFB-033A-40A2-BC8A-388F6DAA973AQ37441711-17C996CC-97BE-4197-8A65-5B744A037450Q37685880-A2AEBB89-46FE-42F8-8E2F-140248D81A9DQ37703880-F91FE397-B33B-4310-AA5B-28BA70764C9BQ37737306-BA88C9AE-CE66-40A3-B461-2BBADF7BE8D6Q37834470-183CD015-7B87-4FF7-9892-64057A52FB70Q38079621-22EAD50B-19AF-4019-A295-FAF8008B7873Q38285639-669B650C-AA01-4CC3-8820-9FF27F9A8791Q38306036-1CD9C66F-FE1C-4505-96AA-DDF2AB8194B7Q38663131-1D0A23EF-95E1-424D-BE9E-296BB186F897Q38794561-CD163DE1-4B6D-4012-9EBA-5213513DFA53Q38968422-AB4A5716-1BE3-4EC9-A90F-816FA9A37619Q39193902-645086F6-D95A-4F64-BA72-7C312349BEC1
P2860
Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Added value of ovarian reserve ...... dividual patient data approach
@ast
Added value of ovarian reserve ...... dividual patient data approach
@en
Added value of ovarian reserve ...... dividual patient data approach
@nl
type
label
Added value of ovarian reserve ...... dividual patient data approach
@ast
Added value of ovarian reserve ...... dividual patient data approach
@en
Added value of ovarian reserve ...... dividual patient data approach
@nl
prefLabel
Added value of ovarian reserve ...... dividual patient data approach
@ast
Added value of ovarian reserve ...... dividual patient data approach
@en
Added value of ovarian reserve ...... dividual patient data approach
@nl
P2093
P2860
P3181
P356
P1476
Added value of ovarian reserve ...... dividual patient data approach
@en
P2093
Ben-Willem J Mol
Brent C Opmeer
Frank J M Broekmans
Jeroen van Disseldorp
Kimiko A Broeze
Madeleine Dolleman
Marinus J C Eijkemans
Patrick Bossuyt
Simone L Broer
P2860
P3181
P356
10.1093/HUMUPD/DMS041
P407
P577
2013-01-01T00:00:00Z